Candel Therapeutics Welcomes New Board Member Maha Radhakrishnan
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a biopharmaceutical company dedicated to creating transformative immunotherapies for cancer treatment, recently announced an important addition to its leadership team. Dr. Maha Radhakrishnan has been appointed to the Company’s Board of Directors, a move that signifies a key strategic development for Candel as it progresses towards its future goals.
Expertise that Matters
Paul Peter Tak, M.D., Ph.D., FMedSci, the President and CEO of Candel, expressed his enthusiasm about Dr. Radhakrishnan's appointment. "We are delighted to welcome Maha as a new member of Candel’s Board," he noted. Her extensive experience in the pharmaceutical industry will be instrumental as Candel ramps up its late-stage oncology programs, aiming for commercial viability to help patients facing significant medical challenges.
Role as a Board Member
Dr. Radhakrishnan brings over two decades of experience in product development and commercialization to her new board role. Her background will be particularly beneficial as the Company prepares for the submission of its Biologics License Application (BLA) for CAN-2409, targeting patients with intermediate-to-high-risk prostate cancer. This submission is anticipated to take place in the near future, representing a significant step forward for Candel.
Innovative Cancer Therapies
Dr. Radhakrishnan is passionate about the potential of Candel's groundbreaking therapies. “I am honored to join the Board at this pivotal moment as Candel advances its innovative immunotherapy candidates across multiple cancer indications,” she remarked. Her belief in the Company’s multimodal approach aligns with Candel’s mission to tackle the serious unmet needs of cancer patients through advanced treatment options.
Background and Experience
Before joining Candel, Dr. Radhakrishnan held significant roles, including serving as an Executive Partner at Sofinnova Investments, which focuses on life sciences and VC initiatives. Her track record includes leadership positions in renowned companies such as Biogen, where she was the Chief Medical Officer, and Sanofi S.A., further solidifying her reputation in the industry.
About Candel Therapeutics
Candel Therapeutics is firmly dedicated to developing off-the-shelf biological immunotherapies aimed at creating personalized anti-tumor immune responses. The Company has established two innovative platforms for its therapies, focusing on genetically modified adenovirus and herpes simplex virus (HSV) constructs. One of their key products, CAN-2409, is recognized as a flagship candidate produced from the adenovirus platform.
Recently, Candel successfully concluded phase 2a clinical trials for CAN-2409, demonstrating positive outcomes in treating non-small cell lung cancer and pancreatic ductal adenocarcinoma. Furthermore, the Company is conducting a pivotal phase 3 clinical trial for localized prostate cancer, under a Special Protocol Assessment with the FDA, showcasing their commitment to rigorous development standards.
Regulatory Designations and Approvals
The FDA has recognized CAN-2409’s potential through multiple designations, including Fast Track Designation for its application in treating stage III/IV NSCLC and Orphan Drug Designation for PDAC. These acknowledgments highlight both Candel’s innovative approach and dedication to addressing critical healthcare needs.
Looking Forward
As Candel expands its research and development capabilities, the future looks promising under the guidance of their experienced board. The combined efforts of Candel’s leadership and the expertise of members like Dr. Radhakrishnan pave the way for continued advancements in cancer treatments, ensuring that they meet the substantial challenges faced by patients today.
Frequently Asked Questions
Who is Maha Radhakrishnan?
Maha Radhakrishnan, M.D., is a newly appointed member of Candel Therapeutics' Board of Directors, bringing over 20 years of industry experience.
What is the role of Candel Therapeutics?
Candel Therapeutics focuses on developing innovative biological immunotherapies aimed at treating various types of cancer.
What is CAN-2409?
CAN-2409 is a product candidate from Candel's adenovirus platform targeting prostate cancer, currently preparing for regulatory submission.
What recent achievements has Candel made?
Candel recently completed successful phase trials for CAN-2409 in lung and pancreatic cancers, showcasing the effectiveness of their treatments.
What impact could Dr. Radhakrishnan's appointment have?
Dr. Radhakrishnan's vast experience in the biopharma industry is expected to provide valuable insights and guidance as Candel progresses its development initiatives.
